Cohort study observes biliary outcomes associated with GLP-1 receptor agonist therapy in youths with overweight or obesity, highlighting safety profiles during treatment.
This cohort study explores biliary outcomes associated with use of glucagon-like peptide-1 receptor agonists in youths aged 12 to 21 years with overweight or obesity diagnosis.
No takes yet. Share an insight, caveat, or question.
Filho et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: